- Home
- Publications
- Publication Search
- Publication Details
Title
Pazopanib: a Review in Advanced Renal Cell Carcinoma
Authors
Keywords
-
Journal
Targeted Oncology
Volume 12, Issue 4, Pages 543-554
Publisher
Springer Nature
Online
2017-06-29
DOI
10.1007/s11523-017-0511-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) B. Escudier et al. ANNALS OF ONCOLOGY
- Medical treatment of renal cancer: new horizons
- (2016) Basma Greef et al. BRITISH JOURNAL OF CANCER
- Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma
- (2016) Jennifer L. Beaumont et al. CANCER
- Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features
- (2016) Jwa Hoon Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
- (2016) Jose Manuel Ruiz-Morales et al. EUROPEAN JOURNAL OF CANCER
- A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma
- (2016) Moon Jin Kim et al. BMC Urology
- Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib
- (2016) Elizabeth MacLean et al. Journal of Managed Care & Specialty Pharmacy
- Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study
- (2015) B. Pérez-Valderrama et al. ANNALS OF ONCOLOGY
- Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a sin
- (2015) Marc R. Matrana et al. BJU INTERNATIONAL
- HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer
- (2015) C.-F. Xu et al. CLINICAL CANCER RESEARCH
- First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting
- (2015) Nicholas J. Vogelzang et al. Clinical Genitourinary Cancer
- Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients
- (2015) Patrick N. Racsa et al. CURRENT MEDICAL RESEARCH AND OPINION
- Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients
- (2015) Thomas Powles et al. EUROPEAN JOURNAL OF CANCER
- 2604 Liver toxicity associated with the use of Pazopanib in renal cancer patients: UK teaching hospital experience
- (2015) A. Jain et al. EUROPEAN JOURNAL OF CANCER
- Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib
- (2015) Michael W. Kattan et al. ONCOLOGY
- Health Care Costs Among Renal Cancer Patients Using Pazopanib and Sunitinib
- (2015) Ryan N. Hansen et al. Journal of Managed Care & Specialty Pharmacy
- Persistence and Compliance Among U.S. Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: A Retrospective Claims Analysis
- (2015) Stacey A. DaCosta Byfield et al. Journal of Managed Care & Specialty Pharmacy
- Health Care Costs Among Renal Cancer Patients Using Pazopanib and Sunitinib
- (2015) Elizabeth A. MacLean et al. Journal of Managed Care & Specialty Pharmacy
- Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States
- (2015) Thomas E. Delea et al. Journal of Managed Care & Specialty Pharmacy
- Outcomes of Patients With Metastatic Renal Cell Carcinoma and End-Stage Renal Disease Receiving Dialysis and Targeted Therapies: A Single Institution Experience
- (2014) Aditya V. Shetty et al. Clinical Genitourinary Cancer
- Pazopanib: A Review of Its Use in the Management of Advanced Renal Cell Carcinoma
- (2014) Paul L. McCormack DRUGS
- Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
- (2014) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib
- (2014) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Open-Label Extension Study to Evaluate Safety and Efficacy of Pazopanib in Patients with Advanced Renal Cell Carcinoma
- (2014) Cora N. Sternberg et al. ONCOLOGY
- Cost-Utility Analysis of Pazopanib Verse Sunitinib as First-Line Treatment of Metastatic Renal Cell Carcinoma (MRCC) iN Spain
- (2014) J. Espinosa et al. VALUE IN HEALTH
- Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms†
- (2013) R. J. Motzer et al. ANNALS OF ONCOLOGY
- Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain
- (2013) Guillermo Villa et al. BMC CANCER
- First line treatment of metastatic renal cell carcinoma
- (2013) Roberto Iacovelli et al. CANCER BIOLOGY & THERAPY
- A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
- (2013) Cora N. Sternberg et al. EUROPEAN JOURNAL OF CANCER
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer
- (2012) C. F. Xu et al. ANNALS OF ONCOLOGY
- Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial
- (2011) D. Cella et al. EUROPEAN JOURNAL OF CANCER
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
- (2009) R Kumar et al. BRITISH JOURNAL OF CANCER
- Phase I Trial of Pazopanib in Patients with Advanced Cancer
- (2009) H. I. Hurwitz et al. CLINICAL CANCER RESEARCH
- Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
- (2008) Robert J. Motzer et al. CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started